文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌近距离放疗:剂量依赖性生物标志物与生活质量的探索性研究

Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life.
PubMed 文献 · Radiat Oncol · 2017-03-14

该前瞻性探索性研究纳入12例接受125I永久性前列腺近距离放疗(PPB)单药治疗(145Gy)的局限性前列腺癌患者,评估植入后CT剂量学、外周血γH2AX/53BP1焦点水平与急性及晚期肠道、泌尿和性毒性之间的相关性。结果显示,植入后24小时γH2AX/53BP1焦点相对基线的早期升高与晚期肠道症状呈正相关,而剂量指标与焦点计数未见相关性。

要点

  • 植入后24小时γH2AX/53BP1焦点相对基线升高与晚期肠道症状正相关。
  • 前列腺整体或分区剂量与γH2AX/53BP1焦点计数之间未观察到相关性。
  • 急性毒性与晚期毒性在泌尿和肠道症状方面均呈高度正相关。

核心结论

  • 植入后24小时γH2AX/53BP1焦点相对基线的早期升高可能有助于评估PPB患者晚期放疗相关毒性风险。
  • 需要更大样本的后续研究验证上述发现。

研究设计与样本

  • 前瞻性探索性(概念验证)研究,纳入12例接受125I PPB单药治疗(145Gy)的前列腺癌患者。
  • 植入后CT剂量学评估全前列腺D90%、12个前列腺分区剂量以及直肠和膀胱的D0.1cc与D2cc。
  • 每例患者采集6份血样:治疗前、植入后1小时、4小时、24小时、4周和3个月,用免疫荧光抗体检测γH2AX/53BP1焦点。
  • 采用EPIC量表在基线、1个月、3个月、6个月、9个月、1年、2年和3年进行患者自评生活质量。
  • 使用Spearman相关系数评估γH2AX/53BP1时序变化、剂量与毒性之间的相关性,最短随访2年。

主要发现

  • 全组平均前列腺D90%为144.6 ± 12.1 Gy,直肠D0.1cc为153.0 ± 30.8 Gy、D2cc为62.7 ± 12.1 Gy,膀胱D0.1cc为123.1 ± 27.0 Gy、D2cc为70.9 ± 11.9 Gy。
  • EPIC评分相对基线的变化显示,泌尿和肠道症状的急性毒性与晚期毒性均呈高度正相关。
  • 植入后24小时γH2AX/53BP1焦点相对基线增加与晚期肠道症状呈正相关。
  • 前列腺整体或分区剂量与γH2AX/53BP1焦点计数之间整体未观察到相关性。

临床怎么用

  • 对于接受PPB的前列腺癌患者,植入后24小时外周血γH2AX/53BP1焦点检测或可作为晚期肠道毒性风险的早期评估指标。
  • 标准CT植入后剂量学与晚期毒性相关性不佳,可结合生物标志物进行风险分层。

局限性

  • 探索性研究样本量小(12例),结论需更大队列验证。
  • 最短随访2年,部分患者随访至3年,长期数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose-rate permanent prostate brachytherapy (PPB) is an attractive treatment option for patients with localised prostate cancer with excellent outcomes. As standard CT-based post-implant dosimetry often correlates poorly with late treatment-related toxicity, this exploratory (proof of concept) study was conducted to investigate correlations between radiation - induced DNA damage biomarker levels, and acute and late bowel, urinary, and sexual toxicity. METHODS: Twelve patients treated with 125I PPB monotherapy (145Gy) for prostate cancer were included in this prospective study. Post-implant CT based dosimetry assessed the minimum dose encompassing 90% (D90%) of the whole prostate volume (global), sub-regions of the prostate (12 sectors) and the near maximum doses (D0.1cc, D2cc) for the rectum and bladder. Six blood samples were collected from each patient; pre-treatment, 1 h (h), 4 h, 24 h post-implant, at 4 weeks (w) and at 3 months (m). DNA double strand breaks were investigated by staining the blood samples with immunofluorescence antibodies to γH2AX and 53BP1 proteins (γH2AX/53BP1). Patient self-scored quality of life from the Expanded Prostate Cancer Index Composite (EPIC) were obtained at baseline, 1 m, 3 m, 6 m, 9 m, 1 year (y), 2y and 3y post-treatment. Spearman's correlation coefficients were used to evaluate correlations between temporal changes in γH2AX/53BP1, dose and toxicity. RESULTS: The minimum follow up was 2 years. Population mean prostate D90% was 144.6 ± 12.1 Gy and rectal near maximum dose D0.1cc = 153.0 ± 30.8 Gy and D2cc = 62.7 ± 12.1 Gy and for the bladder D0.1cc = 123.1 ± 27.0 Gy and D2cc = 70.9 ± 11.9 Gy. Changes in EPIC scores from baseline showed high positive correlation between acute toxicity and late toxicity for both urinary and bowel symptoms. Increased production of γH2AX/53BP1 at 24 h relative to baseline positively correlated with late bowel symptoms. Overall, no correlations were observed between dose metrics (prostate global or sector doses) and γH2AX/53BP1 foci counts. CONCLUSIONS: Our results show that a prompt increase in γH2AX/53BP1foci at 24 h post-implant relative to baseline may be a useful measure to assess elevated risk of late RT - related toxicities for PPB patients. A subsequent investigation recruiting a larger cohort of patients is warranted to verify our findings.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Osman SO, Horn S, Brady D, et al. Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. Radiat Oncol. 2017. PMID: 28288658. doi:10.1186/s13014-017-0792-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。